Hemminki, Akseli - Department of Biosciences, University of Helsinki

Advanced Search

Hemminki, Akseli - Department of Biosciences, University of Helsinki

Introduction Although chemotherapeutics and radiation therapy
Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses
Calcium Gluconate in Phosphate Buffered Saline Increases Gene Delivery with Adenovirus Type 5
THE JOURNAL OF GENE MEDICINE RESEARCH ARTICLE J Gene Med 2003; 5: 300310.
Abstract. Gene therapy is an exciting novel approach for treating cancers resistant to currently available modalities.
TRENDS IN MOLECULAR MEDICINE Adenoviruses for treatment of cancer
www.thelancet.com/oncology Published online November 10, 2009 DOI:10.1016/S1470-2045(09)70307-9 1 Adjuvant capecitabine in combination with docetaxel
CGTG WELCOME-BOOK 1.1. Getting started in CGTG
Multimerization of adenovirus serotype 3 fiber knob domains is required for efficient binding of virus to desmoglein 2 and subsequent opening of epithelial junctions.
The American Society of Gene & Cell Therapy letter to the editor
ORIGINAL ARTICLE In vivo and in vitro distribution of type 5 and fiber-modified
ORIGINAL ARTICLE Oncolytic adenovirus based on serotype 3
Safety of Glucocorticoids in Cancer Patients Treated with Oncolytic Adenoviruses
RESEARCH Open Access Adenoviruses with an avb integrin targeting
Clinical Studies Oncolytic Adenovirus Coding for Granulocyte Macrophage
ORIGINAL ARTICLE Prolonged systemic circulation of chimeric oncolytic
Cancer gene therapy with oncolytic adenoviruses K. Guse,A. Hemminki
Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage
doi:10.1182/blood-2009-05-222463 Prepublished online Nov 12, 2009;
JOURNAL OF VIROLOGY, Jan. 2010, p. 856866 Vol. 84, No. 2 0022-538X/10/$12.00 doi:10.1128/JVI.00692-09
Acta Oncologica, 20 0; 49: 1171191 Correspondence: Akseli Hemminki, Cancer Gene Therapy Group, Transplantation Laboratory and Finnish Institute of Molecular Medicine, University of
Cancer Therapy: Preclinical Targeted Radiotherapy for Prostate Cancer with an Oncolytic
THE JOURNAL OF GENE MEDICINE RESEARCH ARTICLE J Gene Med 2009; 11: 966977.
Brief Report Replacement of Adenovirus Type 5 Fiber Shaft
ORIGINAL ARTICLE Ad5/3-9HIF-D24-VEGFR-1-Ig, an infectivity
Systemic Therapy for Cervical Cancer with Potentially Regulatable Oncolytic Adenoviruses
Tissue-Specific Promoters Active in CD44+ Cancer Cells
PLEASE SCROLL DOWN FOR ARTICLE This article was downloaded by: [Viikin Tiedekirjasto]
Current Gene Therapy, 2008, 8, 000-000 1 1566-5232/08 $55.00+.00 2008 Bentham Science Publishers Ltd.
THE JOURNAL OF GENE MEDICINE RESEARCH ARTICLE J Gene Med 2008; 10: 744753.
Oncolytic adenovirus Ad5/3-24 and chemotherapy for treatment of orthotopic ovarian cancer
ORIGINAL ARTICLE Utility of TK/GCV in the context of highly effective
Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer
Treatment of prostate cancer with Ad5/3#24hCG allows non-invasive detection of the magnitude
ORIGINAL ARTICLE A three-dimensional assay for measurement of viral-induced
THE JOURNAL OF GENE MEDICINE RESEARCH ARTICLE J Gene Med 2007; 9: 39.
Gene Transfer Approaches for Gynecological Diseases Mari Raki,1,2
Triple-Targeted Oncolytic Adenoviruses Featuring the Cox2 Promoter, E1A Transcomplementation, and
Infectivity-Enhanced Adenoviruses Deliver Efficacy in Clinical Samples and Orthotopic Models of Disseminated Gastric Cancer
RESEARCH ARTICLE Combination of gemcitabine and Ad5/3-D24, a tropism
MINI REVIEW MODIFIED ADENOVIRUSES FOR CANCER GENE THERAPY
Enhanced Therapeutic Efficacy for Ovarian Cancer with a Serotype 3 Receptor-Targeted Oncolytic Adenovirus
A Canine Conditionally Replicating Adenovirus for Evaluating Oncolytic Virotherapy
Transcriptional Targeting for Ovarian Cancer Gene Therapy E. Casado,*,
C282Y mutated protein (i.e., differential allele expression, HFE protein accumulation in the endoplasmic reticulum, or degradation of
ADENOVIRAL GENE THERAPY FOR OVARIAN CANCER
ORIGINAL ARTICLE A modified E2F-1 promoter improves the efficacy
RESEARCH ARTICLE Noninvasive dual modality in vivo monitoring
THE JOURNAL OF GENE MEDICINE RESEARCH ARTICLE J Gene Med 2004; 6: 13331342.
ORIGINAL ARTICLE A heparan sulfate-targeted conditionally replicative
Nature Macmillan Publishers Ltd 1998 letters to nature
HUMAN GENE THERAPY 18:627641 (July 2007) Mary Ann Liebert, Inc.
Analysis of Epithelial and Mesenchymal Markers in Ovarian Cancer Reveals Phenotypic Heterogeneity and
Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation
Cancer Therapy: Preclinical Targeted Chemotherapy for Head and Neck Cancer with a
[CANCER RESEARCH 63, 847853, February 15, 2003] Modulation of Coxsackie-Adenovirus Receptor Expression for Increased Adenoviral
[CANCER RESEARCH 61, 63776381, September 1, 2001] Advances in Brief
Cancer Therapy: Clinical Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced
A New Generation of Serotype Chimeric Infectivity-Enhanced CRAds: The Safety Profile of Ad5/3-24 in Advance of a Phase I Clinical Trial in Ovarian Cancer Patients
[CANCER RESEARCH 62, 42734281, August 1, 2002] Adenoviral Gene Therapy for Renal Cancer Requires Retargeting to Alternative
Subscriber access provided by UNIVERSITY OF HELSINKI | University of Helsinki Libraries Molecular Pharmaceutics is published by the American Chemical Society. 1155
Noninvasive Imaging for Evaluation of the Systemic Delivery of Capsid-Modified Adenoviruses in an
10.1517/14712598.7.9.1 2007 Informa UK Ltd ISSN 1471-2598 1 1. Introduction
ORIGINAL ARTICLE Luciferase imaging for evaluation of oncolytic
The new england journal of medicine n engl j med 354;8 www.nejm.org february 23, 2006 809
THE JOURNAL OF GENE MEDICINE RESEARCH ARTICLE J Gene Med 2005; 7: 898907.
EVALUATION OF A SELECTIVELY ONCOLYTIC ADENOVIRUS FOR LOCAL AND SYSTEMIC TREATMENT OF CERVICAL CANCER
AcceptedArticle Switching the fiber knob of oncolytic adenoviruses to avoid
MOLECULAR THERAPY Vol. 4, No. 3, September 2001 Copyright The American Society of Gene Therapy
Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors
[CANCER RESEARCH 62, 12661270, March 1, 2002] Advances in Brief
Microsatellite Instability Is a Favorable Prognostic Indicator in Patients With Colorectal Cancer Receiving Chemotherapy
THE JOURNAL OF GENE MEDICINE RESEARCH ARTICLE J Gene Med 2010; 12: 435445.
A rt i c l e s 96 VOLUME 17 | NUMBER 1 | JANUARY 2011 nAture medicine
Gene-Expression Profiling Predicts Recurrence in Dukes' C Colorectal Cancer
Research Article Epithelial Phenotype Confers Resistance of Ovarian Cancer
From molecular changes to customised therapy A. Hemminki*,1
Advances in Brief CD40 Is Expressed on Ovarian Cancer Cells and Can Be Utilized
ORIGINAL ARTICLE Changing the adenovirus fiber for retaining gene
Serotype Chimeric and Fiber-Mutated Adenovirus Ad5=19p-HIT for Targeting Renal Cancer
1. Introduction 2. Preclinical data on VV for
RESEARCH ARTICLE A cyclooxygenase-2 promoter-based conditionally
JOURNAL OF VIROLOGY, Nov. 2008, p. 1100911015 Vol. 82, No. 22 0022-538X/08/$08.00 0 doi:10.1128/JVI.01608-08
In Vivo Molecular Chemotherapy and Noninvasive Imaging With an Infectivity-Enhanced Adenovirus
MOLECULAR THERAPY Vol. 5, No. 6, June 2002 Copyright The American Society of Gene Therapy
doi:10.1136/bmj.332.7540.501 2006;332;501-502BMJ
Identifying the Safety Profile of Ad5.SSTR/TK.RGD, a Novel Infectivity-Enhanced Bicistronic Adenovirus, in Anticipation of a
Defects in Innate Immunity Render Breast Cancer Initiating Cells Permissive to Oncolytic Adenovirus
Oncolytic Adenoviruses Kill Breast Cancer Initiating CD44+CD24/Low
Strategies to Accomplish Targeted Expression of Transgenes in Ovarian Cancer for Molecular Therapeutic Applications1
Adenoviruses in Oncology A Viable Option?
original article The American Society of Gene & Cell Therapy Molecular Therapy 1
Targeting Adenovirus to the Serotype 3 Receptor Increases Gene Transfer Efficiency to Ovarian Cancer Cells1
ORIGINAL ARTICLE Extended release of adenovirus from silica implants
CLINICAL INVESTIGATION Prostate A PHASE I/II TRIAL OF GEFITINIB GIVEN CONCURRENTLY WITH RADIOTHERAPY
HUMAN GENE THERAPY 13:15051514 (August 10, 2002) Mary Ann Liebert, Inc.
Capsid modifications overcome low heterogeneous expression of heparan sulfate proteoglycan that limits AAV2-mediated gene transfer and therapeutic